Chelsea is an associate in Cooley’s general corporate practice group, where she advises private and public companies in a wide range of industries and through various stages of the business life cycle.
LB Pharmaceuticals Announces $285 Million Upsized IPO
September 12, 2025
Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).
Mott Corporation Agrees to Sell to IDEX Corporation for $1 Billion
July 23, 2024
Cooley advised Mott Corporation – a microfiltration business specializing in the design, customization, and manufacturing of sintered porous metal components and engineered solutions used in fluidic applications – on its definitive agreement to sell to IDEX Corporation for cash consideration of $1 billion, subject to customary adjustments.
